Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.
// request.cf · coarse context
A page that knows where it met you.
Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.
Structure of CYB2108D, a deuterated analogue of 2C-T-36 (CYB2108; CYB210010).[4][5]
HLP005 is a phenethylaminederivative and a deuteratedcompound.[2][3][1] The exact chemical structure of HLP005 does not yet seem to have been disclosed.[2][1] However, it appears to be closely related to CYB210010 (CYB2108; 2C-T-36 or 2C-T-TFM), which itself is non-deuterated.[6][7][8] In addition, HLP005's developer has patent protection for HLP005, indicating that its chemical structure has been published in the patent literature.[2][6][4] Some notable phenethylamines patented by Helus Pharma include the non-deuterated CYB2108 (2C-T-36) and its deuterated form CYB2108D (fully deuterated methoxy groups at 2 and 5 positions).[4][5]
12345678Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, Lucke-Wold B (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci. 23 (24) 15777. doi:10.3390/ijms232415777. PMC9779201. PMID36555419. Table 1. Biochemical structures, mechanisms, and receptor functions of twenty psychoceutical drugs.: [...] Drug Name: Phenethylamine derivative (CYB005): Chemical Structure: *. Target type: –. Method of Action: CYB005 inhibits serotonin and dopamine transporters within the synaptic cleft. [...] These drugs generally bind to CNS G-protein receptors within the 5-HT family, such as 5-HT1A, 5-HT2A, and 5-HT2B, and act agonistically [9,13–15,17,18]. Additionally, two of these, ecstasy and CYB005 (phenethylamine derivative [20]), block the reuptake of serotonin, increasing the serotonin levels within the synaptic cleft [12,21,22]. [...] According to preclinical data, CYB005, a phenethylamine derivative, aims to inhibit serotonin transporters within the synaptic cleft [20–22]. [...] Studies on [...] CYB005 [...] were not found in the literature search, so this information was obtained through the websites of their respective pharmaceutical companies. [...] Table 2. Highlights of the psychoceutical benefits.: Drug: CYB005 (Phenethylamine derivative). Benefit: Treats neuroinflammation and psychiatric conditions. [...] Three [deuterated] drugs that researchers have been working on are [...] CYB005 (for neuroinflammation). [...] Finally, CYB005 is a phenethylamine derivative currently in preclinical development [55], which has the potential to treat neuroinflammation and psychiatric conditions [20]. [...] Of the 20 drugs, [...] CYB005 [...] do not currently have completed clinical trials.
12345678"CYB 005". AdisInsight. 28 October 2024. Retrieved 10 November 2024. CYB 005 is a phenethylamine derivative is being developed by Cybin for the treatment of treatment resistant psychiatric disorders.
↑Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". J Med Chem. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID38593423.
